Top

Published in:

01-10-2016 | Original Article

Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study

Authors: Suporn Chuncharunee, Raymond Wong, Ponlapat Rojnuckarin, Cheng-Shyong Chang, Kian Meng Chang, Meng-Yao Lu, Wen-Li Hwang, Liang Piu Koh, Tsai-Yun Chen, Anskar YH Leung, Lalita Norasetthada, Shih-Chung Wang, Ming-Chih Chang, Kang-Hsi Wu, Surapol Issaragrisil

Published in: International Journal of Hematology | Issue 4/2016

Abstract

Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5–3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 %, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 %, respectively. The 2-year OS rate was 86.3 %. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.

Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–19.CrossRefPubMedPubMedCentral

Montané E, Ibáñez L, Vidal X, Ballarín E, Puig R, García N, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93:518–23.CrossRefPubMed

Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, et al. The epidemiology of aplastic anemia in Thailand. Blood. 2006;107:1299–307.CrossRefPubMedPubMedCentral

Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297–304.CrossRefPubMed

Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;14:43–70.CrossRef

Shin SH, Lee SE, Lee WL. Recent advances in treatment of aplastic anemia. Korean J Intern Med. 2014;29:713–26.CrossRefPubMedPubMedCentral

Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematol Am Soc Hematol Educ Program. 2012;2012:292–300.

Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430–8.CrossRefPubMedPubMedCentral

Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2010;89:851–9.CrossRefPubMed

10.

Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, Eom KS, et al. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2013;92:817–24.CrossRefPubMed

11.

Chang MH, Kim KH, Kim HS, Jun HJ, Kim DH, Jang JH, et al. Predictors of response to immunosuppressive therapy with Antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol. 2009;84:154–9.CrossRefPubMed

12.

Yamazaki H, Saito C, Sugimori N, Hosokawa K, Kiyu Y, Mochizuki K, et al. Thymoglobulin is as effective as lymphoglobulin in Japanese patients with aplastic anemia possessing increased GPIAP deficient cells. ASH Annu Meet Abstr. 2011;118:1339.

13.

Jeong DC, Chung NG, Cho B, Zou Y, Ruan M, Takahashi Y, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica. 2014;99:664–71.CrossRefPubMedPubMedCentral

14.

Afable MG, Shaik M, Sugimoto Y, Elson P, Clemente M, Makishima H, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011;96:1269–75.CrossRefPubMedPubMedCentral

15.

Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012;119:5391–6.CrossRefPubMed

16.

Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007;110:1756–61.CrossRefPubMed

17.

Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011;117:4434–41.CrossRefPubMed

18.

Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058–65.PubMed

Title: Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study
Authors: Suporn Chuncharunee
Raymond Wong
Ponlapat Rojnuckarin
Cheng-Shyong Chang
Kian Meng Chang
Meng-Yao Lu
Wen-Li Hwang
Liang Piu Koh
Tsai-Yun Chen
Anskar YH Leung
Lalita Norasetthada
Shih-Chung Wang
Ming-Chih Chang
Kang-Hsi Wu
Surapol Issaragrisil
Publication date: 01-10-2016
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 4/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-016-2053-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis

Atypical amyloid deposits

Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP

CLL with intra-cytoplasmic lymphocytic inclusion bodies

Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations

Ruxolitinib dose management as a key to long-term treatment success

Keynote webinar | Spotlight on antibody–drug conjugates in cancer